

# Dihua Yu

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/589566/dihua-yu-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160  
papers

15,192  
citations

63  
h-index

122  
g-index

172  
ext. papers

17,433  
ext. citations

10.1  
avg, IF

6.34  
L-index

#	Paper	IF	Citations
160	miR-7/TGF- axis sustains acidic tumor microenvironment-induced lung cancer metastasis.. <i>Acta Pharmaceutica Sinica B</i> , <b>2022</b> , 12, 821-837	15.5	2
159	An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response.. <i>STAR Protocols</i> , <b>2022</b> , 3, 101198	1.4	0
158	Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer.. <i>Journal of Biological Chemistry</i> , <b>2022</b> , 101817	5.4	2
157	EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin α-FAK activation.. <i>Nature Communications</i> , <b>2022</b> , 13, 2543	17.4	1
156	Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. <i>American Journal of Cancer Research</i> , <b>2021</b> , 11, 236-250	4.4	2
155	Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer. <i>American Journal of Cancer Research</i> , <b>2021</b> , 11, 2005-2024	4.4	1
154	The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. <i>Cancer Cell</i> , <b>2021</b> ,	24.3	15
153	TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	20
152	Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. <i>Nature Communications</i> , <b>2021</b> , 12, 2788	17.4	3
151	Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. <i>Oncogene</i> , <b>2021</b> , 40, 4992-5001	9.2	16
150	Targeting the α integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	17
149	Tumor microenvironment as a therapeutic target in cancer. <i>Pharmacology &amp; Therapeutics</i> , <b>2021</b> , 221, 107753	13.9	41
148	Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. <i>Acta Neuropathologica</i> , <b>2021</b> , 141, 303-321	14.3	8
147	Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. <i>Nature Communications</i> , <b>2021</b> , 12, 832	17.4	60
146	Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	29
145	The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. <i>Journal of Biomedical Science</i> , <b>2020</b> , 27, 77	13.3	30
144	EXTH-06. INTEGRATED MOLECULAR PROFILING REVEALS TARGETABLE MOLECULAR ABNORMALITIES SHARED ACROSS MULTIPLE HISTOLOGIES OF BRAIN METASTASIS. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii87-ii88	1	

143	Brain Metastasis Organotropism. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2020</b> , 10,	5.4	11
142	Proteomics analysis of the matrisome from MC38 experimental mouse liver metastases. <i>American Journal of Physiology - Renal Physiology</i> , <b>2019</b> , 317, G625-G639	5.1	3
141	Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer. <i>Cancer Research</i> , <b>2019</b> , 79, 4211-4226	10.1	35
140	Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. <i>Nature Immunology</i> , <b>2019</b> , 20, 835-851	19.1	147
139	The importance of developing therapies targeting the biological spectrum of metastatic disease. <i>Clinical and Experimental Metastasis</i> , <b>2019</b> , 36, 305-309	4.7	7
138	Exosomes in cancer development, metastasis, and immunity. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2019</b> , 1871, 455-468	11.2	189
137	Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?. <i>Cell and Bioscience</i> , <b>2019</b> , 9, 82	9.8	5
136	Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells. <i>Cancer Research</i> , <b>2018</b> , 78, 2248-2261	10.1	41
135	Brain metastasis: Unique challenges and open opportunities. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2017</b> , 1867, 49-57	11.2	79
134	Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. <i>Cancer Research</i> , <b>2017</b> , 77, 5374-5383	10.1	60
133	Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention. <i>Cancer Prevention Research</i> , <b>2017</b> , 10, 641-650	3.2	4
132	Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis. <i>Journal of Visualized Experiments</i> , <b>2017</b> ,	1.6	11
131	14-3-3 $\sigma$ loss leads to neonatal lethality by microRNA-126 downregulation-mediated developmental defects in lung vasculature. <i>Cell and Bioscience</i> , <b>2017</b> , 7, 58	9.8	2
130	Immunofluorescence <b>2017</b> , 135-150		15
129	JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 4498-4515	15.9	118
128	14-3-3 $\sigma$ loss impedes oncogene-induced mammary tumorigenesis and metastasis by attenuating oncogenic signaling. <i>American Journal of Cancer Research</i> , <b>2017</b> , 7, 1654-1664	4.4	4
127	Advances in decoding breast cancer brain metastasis. <i>Cancer and Metastasis Reviews</i> , <b>2016</b> , 35, 677-684	9.6	4
126	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. <i>Nature Communications</i> , <b>2016</b> , 7, 12632	17.4	408

125	Deubiquitination and Stabilization of PD-L1 by CSN5. <i>Cancer Cell</i> , <b>2016</b> , 30, 925-939	24.3	332
124	Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. <i>American Journal of Cancer Research</i> , <b>2016</b> , 6, 981-95	4.4	3
123	Upregulation of lactate dehydrogenase a by 14-3-3 leads to increased glycolysis critical for breast cancer initiation and progression. <i>Oncotarget</i> , <b>2016</b> , 7, 35270-83	3.3	22
122	HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. <i>Molecular Oncology</i> , <b>2015</b> , 9, 586-600	7.9	23
121	PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 402-11	4.6	31
120	Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. <i>Cancer Research</i> , <b>2015</b> , 75, 4863-75	10.1	31
119	Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. <i>Nature</i> , <b>2015</b> , 527, 100-104	50.4	744
118	Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases. <i>Stem Cells</i> , <b>2015</b> , 33, 2985-94	5.8	38
117	Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. <i>World Journal of Clinical Oncology</i> , <b>2015</b> , 6, 299-311	2.5	22
116	14-3-3 turns TGF-β function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. <i>Cancer Cell</i> , <b>2015</b> , 27, 177-92	24.3	124
115	Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. <i>Oncotarget</i> , <b>2015</b> , 6, 3932-46	3.3	43
114	Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells. <i>American Journal of Cancer Research</i> , <b>2015</b> , 5, 3624-34	4.4	1
113	Enhanced PI3K p110β signaling confers acquired lapatinib resistance that can be effectively reversed by a p110β selective PI3K inhibitor. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 60-70	6.1	31
112	Definition of PKC-β, CDK6, and MET as therapeutic targets in triple-negative breast cancer. <i>Cancer Research</i> , <b>2014</b> , 74, 4822-35	10.1	48
111	Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. <i>Cell Research</i> , <b>2014</b> , 24, 542-59	24.7	20
110	14-3-3 orchestrates mammary tumor onset and progression via miR-221-mediated cell proliferation. <i>Cancer Research</i> , <b>2014</b> , 74, 363-373	10.1	26
109	MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. <i>Science Signaling</i> , <b>2014</b> , 7, ra71	8.8	68
108	Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis. <i>PLoS ONE</i> , <b>2014</b> , 9, e101452	3.7	35

107	S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. <i>American Journal of Translational Research (discontinued)</i> , <b>2014</b> , 6, 361-76	3	30
106	Breast Cancer Multistep Development <b>2014</b> , 1-7		
105	SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. <i>Cancer Research</i> , <b>2013</b> , 73, 5764-74	10.1	89
104	Needle-based fluorescence endomicroscopy via structured illumination with a plastic, achromatic objective. <i>Journal of Biomedical Optics</i> , <b>2013</b> , 18, 096003	3.5	22
103	Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. <i>PLoS ONE</i> , <b>2013</b> , 8, e73406	3.7	27
102	Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. <i>Breast Cancer Research</i> , <b>2012</b> , 14, R4	8.3	39
101	Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. <i>Trends in Pharmacological Sciences</i> , <b>2012</b> , 33, 122-8	13.2	213
100	The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. <i>Cell</i> , <b>2012</b> , 149, 1098-111	56.2	261
99	Growth factor signaling in metastasis: current understanding and future opportunities. <i>Cancer and Metastasis Reviews</i> , <b>2012</b> , 31, 479-91	9.6	23
98	Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 132, 487-98	4.4	20
97	Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. <i>Cancer Research</i> , <b>2012</b> , 72, 4417-28	10.1	36
96	Overexpression of 14-3-3 $\eta$ in cancer cells activates PI3K via binding the p85 regulatory subunit. <i>Oncogene</i> , <b>2012</b> , 31, 897-906	9.2	70
95	High-resolution fiber-optic microendoscopy for in situ cellular imaging. <i>Journal of Visualized Experiments</i> , <b>2011</b> ,	1.6	59
94	Cancer cell migration: integrated roles of matrix mechanics and transforming potential. <i>PLoS ONE</i> , <b>2011</b> , 6, e20355	3.7	37
93	p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. <i>Nature Cell Biology</i> , <b>2011</b> , 13, 317-23	23.4	586
92	Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. <i>Nature Medicine</i> , <b>2011</b> , 17, 461-9	50.5	402
91	BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. <i>Cancer Cell</i> , <b>2011</b> , 20, 341-56	24.3	64
90	Microenvironment determinants of brain metastasis. <i>Cell and Bioscience</i> , <b>2011</b> , 1, 8	9.8	30

89	Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2011</b> , 20, 476-82	4	14
88	Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. <i>Cancer Research</i> , <b>2011</b> , 71, 603-13	10.1	133
87	Nucleolin protein interacts with microprocessor complex to affect biogenesis of microRNAs 15a and 16. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 44095-44103	5.4	53
86	Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3126-32	2.2	179
85	Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. <i>PLoS ONE</i> , <b>2011</b> , 6, e20701	3.7	46
84	Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3126-3132	2.2	2
83	TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. <i>Oncogene</i> , <b>2010</b> , 29, 2047-59	9.2	146
82	Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. <i>PLoS ONE</i> , <b>2010</b> , 5, e13390	3.7	91
81	Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. <i>Cancer Research</i> , <b>2010</b> , 70, 7684-9	10.1	13
80	PI(3)kinase apart PTEN's role in cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4325-30	12.9	196
79	Cancer cell stiffness: integrated roles of three-dimensional matrix stiffness and transforming potential. <i>Biophysical Journal</i> , <b>2010</b> , 99, 2048-57	2.9	117
78	PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 1647-56 <sup>5.8</sup>	5.8	243
77	Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. <i>Biochemical and Biophysical Research Communications</i> , <b>2010</b> , 403, 103-7	3.4	24
76	14-3-3 $\gamma$ as a prognostic marker and therapeutic target for cancer. <i>Expert Opinion on Therapeutic Targets</i> , <b>2010</b> , 14, 1343-54	6.4	99
75	Molecular predictors of response to trastuzumab and lapatinib in breast cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 7, 98-107	19.4	125
74	Breast cancer metastasis: challenges and opportunities. <i>Cancer Research</i> , <b>2009</b> , 69, 4951-3	10.1	152
73	14-3-3 $\zeta$ overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. <i>Cancer Research</i> , <b>2009</b> , 69, 3425-32	10.1	152
72	ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. <i>Molecular Cancer Research</i> , <b>2009</b> , 7, 592-600	6.6	50

71	Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1326-34	12.9	68
70	Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation. <i>Cancer Research</i> , <b>2009</b> , 69, 9163-8	10.1	30
69	14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. <i>Cancer Cell</i> , <b>2009</b> , 16, 195-207	24.3	167
68	Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. <i>Oncogene</i> , <b>2009</b> , 28, 3689-701	9.2	182
67	Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation. <i>Oncogene</i> , <b>2009</b> , 28, 2436-45	9.2	65
66	14-3-3zeta/tau heterodimers regulate Slingshot activity in migrating keratinocytes. <i>Biochemical and Biophysical Research Communications</i> , <b>2009</b> , 383, 450-4	3.4	19
65	ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. <i>Nature Cell Biology</i> , <b>2008</b> , 10, 138-48	23.4	515
64	14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. <i>Cancer Research</i> , <b>2008</b> , 68, 1760-7	10.1	77
63	Ph.D. Training in cancer biology. <i>Cancer Research</i> , <b>2008</b> , 68, 9122-4	10.1	4
62	Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. <i>Molecular Carcinogenesis</i> , <b>2008</b> , 47, 701-6	5	218
61	The Impact of ErbB2 on Cancer Progression and Metastasis through Modulation of Tumor and Tumor Microenvironment <b>2008</b> , 43-56		
60	High prevalence of p53 exon 4 mutations in soft tissue sarcoma. <i>Cancer</i> , <b>2007</b> , 109, 2323-33	6.4	33
59	Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5883-8	12.9	176
58	Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. <i>Molecular Cancer Therapeutics</i> , <b>2007</b> , 6, 1650-60	6.1	101
57	Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. <i>Advances in Experimental Medicine and Biology</i> , <b>2007</b> , 608, 119-29	3.6	96
56	Novel approaches for chemosensitization of breast cancer cells: the E1A story. <i>Advances in Experimental Medicine and Biology</i> , <b>2007</b> , 608, 144-69	3.6	17
55	Adenoviral-Vector Based siRNA for Mutant K-ras as a Promising Tool for Lung Cancer Gene Therapy: A License to Kill. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 1724-5	4.6	
54	Dissection of signaling pathways in fourteen breast cancer cell lines using reverse-phase protein lysate microarray. <i>Technology in Cancer Research and Treatment</i> , <b>2006</b> , 5, 543-51	2.7	21

53	Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. <i>Cancer Research</i> , <b>2006</b> , 66, 8770-8	10.1	64
52	Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. <i>Molecular Cancer Therapeutics</i> , <b>2006</b> , 5, 317-28	6.1	62
51	Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. <i>Cancer Research</i> , <b>2006</b> , 66, 3764-72	10.1	96
50	Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. <i>Molecular Cancer Research</i> , <b>2006</b> , 4, 803-10	6.6	59
49	Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells. <i>Journal of Virology</i> , <b>2006</b> , 80, 383-94	6.6	26
48	ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. <i>Cancer Research</i> , <b>2006</b> , 66, 2028-37	10.1	157
47	Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. <i>Nature Clinical Practice Oncology</i> , <b>2006</b> , 3, 269-80		756
46	Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. <i>Oncogene</i> , <b>2006</b> , 25, 3286-95	9.2	81
45	Mechanisms of Breast Cancer Resistance to Chemotherapy <b>2006</b> , 783-803		
44	A Novel Mechanism of Herceptin Resistance and Counteracting Strategies. <i>Journal of Immunotherapy</i> , <b>2005</b> , 28, 652	5	
43	Mechanisms of trastuzumab resistance and their clinical implications. <i>Annals of the New York Academy of Sciences</i> , <b>2005</b> , 1059, 70-5	6.5	66
42	A knotty turnabout?: Akt1 as a metastasis suppressor. <i>Cancer Cell</i> , <b>2005</b> , 8, 437-9	24.3	26
41	Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. <i>Cancer</i> , <b>2005</b> , 103, 830-8	6.4	77
40	Transcriptional repression of protein kinase C alpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 4825-33	5.4	42
39	ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. <i>Cancer Research</i> , <b>2005</b> , 65, 1858-67	10.1	249
38	A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 217-25	12.9	184
37	Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6779-88	12.9	263
36	Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. <i>Cancer Research</i> , <b>2004</b> , 64, 3479-85	10.1	144

35	Liposomal mediated transfer of ErbB2 antisense DNA: coming of age in the war against cancer. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 205-6	4.6	3
34	PI3K: Missense Mutation Motivates Malignancy. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 776-7	4.6	6
33	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. <i>Cancer Cell</i> , <b>2004</b> , 6, 117-27	24.3	1462
32	Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. <i>Cancer Cell</i> , <b>2004</b> , 6, 459-69	24.3	443
31	ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophosphamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. <i>Cancer</i> , <b>2003</b> , 98, 1123-30	6.4	41
30	Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. <i>Cancer</i> , <b>2003</b> , 98, 1377-85	6.4	94
29	ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. <i>Cancer</i> , <b>2002</b> , 94, 2855-61	6.4	105
28	Characterization of 11 human sarcoma cell strains: evaluation of cytogenetics, tumorigenicity, metastasis, and production of angiogenic factors. <i>Cancer</i> , <b>2002</b> , 95, 1569-76	6.4	10
27	Localizing the EGF receptor - Reply. <i>Nature Cell Biology</i> , <b>2002</b> , 4, E22-E23	23.4	8
26	Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. <i>Molecular Cell</i> , <b>2002</b> , 9, 993-1004	17.6	118
25	Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. <i>Cancer Research</i> , <b>2002</b> , 62, 2034-42	10.1	58
24	Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. <i>Cancer Research</i> , <b>2002</b> , 62, 5703-10	10.1	72
23	E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. <i>Breast Cancer</i> , <b>2001</b> , 8, 285-93	3.4	18
22	Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. <i>Cancer</i> , <b>2001</b> , 92, 1556-66	6.4	60
21	Transcriptional upregulation and activation of p53Cdc via p34(cdc2) in Taxol-induced apoptosis. <i>Oncogene</i> , <b>2001</b> , 20, 2537-43	9.2	18
20	Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. <i>Oncogene</i> , <b>2001</b> , 20, 8066-74	9.2	160
19	Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression <b>2001</b> , 92, 1556		1
18	Role of erbB2 in breast cancer chemosensitivity. <i>BioEssays</i> , <b>2000</b> , 22, 673-80	4.1	97

17	Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity. <i>Cancer Gene Therapy</i> , <b>2000</b> , 7, 422-9	5.4	24
16	C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. <i>Oncogene</i> , <b>2000</b> , 19, 4864-75	9.2	90
15	Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. <i>Oncogene</i> , <b>2000</b> , 19, 6115-21	9.2	312
14	Inhibition of the transcription factor nuclear factor- $\kappa$ B by adenoviral-mediated expression of IBM results in tumor cell death. <i>Surgery</i> , <b>1999</b> , 126, 399-405	3.6	19
13	The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. <i>Cancer and Metastasis Reviews</i> , <b>1998</b> , 17, 195-202	9.6	25
12	The role of oncogenes in drug resistance. <i>Cytotechnology</i> , <b>1998</b> , 27, 283-92	2.2	7
11	Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. <i>Oncogene</i> , <b>1998</b> , 16, 2087-94	9.2	112
10	Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. <i>Molecular Cell</i> , <b>1998</b> , 2, 581-91	17.6	311
9	The role of oncogenes in drug resistance <b>1998</b> , 283-292		0
8	Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1). <i>Journal of the National Cancer Institute</i> , <b>1997</b> , 89, 1524-9	9.7	35
7	Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. <i>Oncogene</i> , <b>1997</b> , 14, 1965-71	9.2	25
6	Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. <i>Oncogene</i> , <b>1997</b> , 15, 953-60	9.2	82
5	HER-2/neu-targeting gene therapy--a review. <i>Gene</i> , <b>1995</b> , 159, 65-71	3.8	58
4	Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. <i>Molecular Carcinogenesis</i> , <b>1992</b> , 5, 213-8	5	100
3	Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1990</b> , 87, 4499-503	11.5	131
2	Targeting the EGFR family of receptor tyrosine kinases843-853		
1	EZH2 Engages TGF $\beta$ Signaling to Promote Breast Cancer Bone Metastasis via Integrin $\alpha$ -FAK Activation		1